Moderna Returns to Profit and Raises Full-Year Revenue Outlook
Moderna posted a $162 million third-quarter profit and raised its 2026 revenue growth outlook to 15% to 25%, Dow Jones Newswires reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Moderna swung to a third-quarter profit of $162 million, against a loss of $200 million a year earlier. Earnings were 38 cents a share, while analysts polled by FactSet had expected a loss of $1.10 a share. Revenue rose 29% to $1.31 billion, well above Wall Street estimates of $890.3 million.
The company now expects full-year total revenue growth of 15% to 25%, up from a previous forecast of up to 10%. It attributed the gain to higher Covid-19 vaccine sales abroad and deliveries under long-term government partnerships. Dow Jones Newswires reported that shares rose 9.6% to $264.79 in premarket trading.
why it matters
The results suggest Covid-19 vaccine demand has stabilized, while Moderna shifts toward oncology and broader mRNA products. Investors will watch how much of the revenue comes from one-off government deliveries and how the Merck partnership on intismeran progresses.
market impact
Biotech and Moderna shares: strong results and a higher outlook support the stock
- Moderna shares pressure up — revenue and profit beat expectations and the growth outlook was raised
tags
instruments
on polymarket
sources
- Moderna Lifts Outlook, Swings to 3Q Profit — Dow Jones Newswires, 6 November 2026 at 12:22 UTC
- Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update, 6 November 2026 at 12:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗